SCHEMBL935771

SCHEMBL935771

COC(=O)c1cccc(C=NO)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.65
GRIN3B O60391 1/20 0.65
GRIN1 Q05586 1/20 0.65
GRIN2A Q12879 1/20 0.65
GRIN2B Q13224 1/20 0.65
GRIN2C Q14957 1/20 0.65
GRIN3A Q8TCU5 1/20 0.65
KDM4E B2RXH2 2/20 0.55
ALOX15 P16050 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KMT2A Q03164 4/20 0.54
MAPT P10636 2/20 0.54
MEN1 O00255 1/20 0.54
P4HB P07237 3/20 0.54
MAPK1 P28482 1/20 0.54
RAB9A P51151 4/20 0.49
NPC1 O15118 2/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL935770 1.00 GRIN2D (0.65) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL16590390 1.00 GRIN2D (0.65) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20861813 0.85 GRIN2D (0.68) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL19439620 0.84 GRIN2D (0.62) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30390191 0.83 KMT2A (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL19300876 0.83 GRIN2D (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL31490543 0.82 KDM4E (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11456160 0.82 P4HB (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4407110 0.82 P4HB (0.68) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11222093 0.82 P4HB (0.68) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114920667-B Electrochemical preparation method of atta Lu Lunzhi 湖南大学 2024-06-21 CN claimed
CN-114920667-B Electrochemical preparation method of atta Lu Lunzhi 湖南大学 2024-06-21 CN disclosed
US-20170204073-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2017-07-20 US disclosed
US-20170137413-A1 NOVEL HALOGEN-SUBSTITUTED COMPOUNDS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2017-05-18 US disclosed
US-9611230-B2 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease PTC THERAPEUTICS, INC. (US) 2017-04-04 US disclosed
CN-106459000-A NOVEL 3-[(PYRAZOL-5-YL)-HETEROARYL]-BENZAMIDE DERIVATIVES 拜耳作物科学股份公司 2017-02-22 CN disclosed
EP-3126353-A1 NOVEL 3-[(PYRAZOL-5-YL)-HETEROARYL]-BENZAMIDE DERIVATIVES AND USE THEREOF AS PEST CONTROL AGENTS Bayer CropScience Aktiengesellschaft (DE) 2017-02-08 EP disclosed
EP-3067053-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC Therapeutics, Inc. (US) 2016-09-14 EP disclosed
EP-1815206-B1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS INC (US) 2016-04-06 EP disclosed
EP-2939674-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC Therapeutics, Inc. (US) 2015-11-04 EP disclosed
EP-1379522-A1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6548495-B2 Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders HOFFMANN-LA ROCHE INC. 2003-04-15 US disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020198197-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed
WO-2002083665-A1 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed
EP-0103957-B1 SUBSTITUTED BENZYL ESTERS, INTERMEDIATES THEREFOR, PROCESSES FOR THEIR PREPARATION AND THE USE OF THE ESTERS AS PESTICIDES NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1988-04-20 EP disclosed
US-4515808-A INSECTICIDES NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1985-05-07 US disclosed
EP-0103957-A2 Substituted benzyl esters, intermediates therefor, processes for their preparation and the use of the esters as pesticides NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137413-A1 NOVEL HALOGEN-SUBSTITUTED COMPOUNDS CYP4F3, PYM1, PRDX4 GRIN2D 2702/4885GRIN3B 3908/4885GRIN1 2450/4885
US-20170204073-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE NSUN2, UPF1, NSUN3 GRIN2D 4479/4885GRIN3B 2342/4885GRIN1 3103/4885
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 GRIN2D 13/4885GRIN3B 27/4885GRIN1 22/4885
US-20020198197-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives BDKRB1, BDKRB2, GRIN1 GRIN2D 9/4885GRIN3B 7/4885GRIN1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.